Repretin (epoetin alfa biosimilar) / SEDICO, Rotapharm - LARVOL DELTA

IDENTIFICATION OF NEW POTENTIAL DRUGGABLE TARGETS IN GASTROINTESTINAL STROMAL TUMOR (GIST) THROUGH RNA SEQUENCING ANALYSIS (AIOM 2022) - "Imatinib, a tyrosinekinase inhibitor is the standard treatment for GISTs; however, many patients develop resistance to this drug and to sunitinib, regorafenib and repretinib (used as second, third and fourth lines of treatment) and so identification of new potential pharmacological targets remains an unmet clinical need. TOP2A may represent a novel druggable target in GIST; further studies will be needed to better understand its role in the carcinogenesis process."

Gastrointestinal Cancer • Gastrointestinal Disorder • Gastrointestinal Stromal Tumor • Oncology • Sarcoma • TOP2A